Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

BACKGROUND: Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b...

Descripción completa

Detalles Bibliográficos
Autores principales: Visseaux, Benoit, Charpentier, Charlotte, Collin, Gilles, Bertine, Mélanie, Peytavin, Gilles, Damond, Florence, Matheron, Sophie, Lefebvre, Eric, Brun-Vézinet, Françoise, Descamps, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527700/
https://www.ncbi.nlm.nih.gov/pubmed/26247470
http://dx.doi.org/10.1371/journal.pone.0134904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527700/
https://www.ncbi.nlm.nih.gov/pubmed/26247470
http://dx.doi.org/10.1371/journal.pone.0134904

Ejemplares similares